Udell Jacob A, Ray Joel G
University of British Columbia, Department of Medicine, Vancouver Hospital and Health Sciences Centre, 2775 Laurel Street, Vancouver, British Columbia, V5Z 1M9, Canada.
Expert Rev Cardiovasc Ther. 2006 Nov;4(6):917-26. doi: 10.1586/14779072.4.6.917.
Statins are effective in the prevention of coronary heart disease (CHD), a leading cause of heart failure (HF). Secondary analyses from 11 randomized clinical trials of patients with high-risk acute or stable coronary heart disease, but without HF, suggest that statins may prevent new-onset HF or HF-related hospitalization. In persons with established HF, several cohort studies found an approximate 35% relative risk reduction in all-cause mortality. While ongoing randomized clinical trials will help to determine the efficacy of statins in persons with established HF, it is reasonable to consider this class of medications in patients with a history of cardiovascular disease, dyslipidemia or diabetes mellitus, and who have either developed, or who remain at risk of, HF.
他汀类药物在预防冠心病(CHD)方面有效,冠心病是心力衰竭(HF)的主要病因。对11项针对高危急性或稳定型冠心病患者但无心力衰竭患者的随机临床试验进行的二次分析表明,他汀类药物可能预防新发心力衰竭或与心力衰竭相关的住院治疗。在已确诊心力衰竭的患者中,几项队列研究发现全因死亡率相对降低约35%。虽然正在进行的随机临床试验将有助于确定他汀类药物对已确诊心力衰竭患者的疗效,但对于有心血管疾病、血脂异常或糖尿病病史且已发生或仍有心力衰竭风险的患者,考虑使用这类药物是合理的。